ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York

ImageneBio (Nasdaq: IMA) announced that CEO Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 at 12:50 PM EDT.

Rhea-AI Summary

ImageneBio (Nasdaq: IMA) announced that CEO Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 at 12:50 PM EDT. A live webcast and 90-day archive will be available on the Imagene investor relations website.

Argus May 28 session

-0.08% close to close Open Argus

Details

News Market Reaction – IMA

On May 28, the first trading day after this news, IMA closed 0.08% below the previous close.

Data tracked by StockTitan Argus for the May 28 session.

Market Context

This announcement highlights ImageneBio’s participation in the Jefferies Global Healthcare Conferenc...

Analysis

This announcement highlights ImageneBio’s participation in the Jefferies Global Healthcare Conference on June 4, 2026, including a 12:50 PM EDT presentation and one-on-one meetings, with a webcast archived for 90 days. It continues a pattern of active investor-relations outreach following recent earnings, a $30 million private placement, and program updates for IMG-007. Investors may watch for any new commentary on trial timelines, capital plans, or strategy that could emerge from conference discussions.

Key Figures

Conference date: June 4, 2026 Presentation time: 12:50 PM EDT Webcast archive duration: 90 days

Conference date

June 4, 2026

Jefferies Global Healthcare Conference presentation

Presentation time

12:50 PM EDT

Jefferies Global Healthcare Conference slot

Webcast archive duration

90 days

Replay availability on ImageneBio IR events page

Historical Context

5 past events · Latest: May 7

5 events

1. May 7

   Earnings and update

   24h Move

   -10.5%

   Q1 2026 results, cash runway into Q1 2028, IMG-007 Phase 2b timing.

2. Apr 13

   Private placement

   24h Move

   +23.4%

   $30M private placement to fund IMG-007 alopecia and dermatitis work.

3. Mar 17

   Equity inducement grants

   24h Move

   -3.2%

   Inducement RSUs and NSOs granted to new hires under 2025 plan.

4. Mar 10

   Earnings and update

   24h Move

   +2.5%

   Q4 and 2025 results, IMG-007 Phase 2b enrollment and cash position.

5. Feb 26

   Conference participation

   24h Move

   +1.6%

   Participation in Leerink Global Healthcare Conference and fireside chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings.

Jefferies Global Healthcare Conference in New York
Date: Thursday, June 4, 2026
Time: 12:50 PM EDT
Webcast: Linked here and archived for 90 days on events page on the Imagene IR website

About ImageneBio, Inc.
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company's program, IMG-007, is a receptor targeting, non-T cell-depleting, ADCC-silenced, anti-OX40 monoclonal antibody with an approximately 5-week half-life. Imagene is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis. The Company has also completed a proof-of-concept trial and plans to initiate a Phase 2 study in alopecia areata.

Company and Investor Contact
Rebecca Cohen
rcohen@imagenebio.com

Media Contact
Jason Braco, PhD
The Health & Science Agency
jason@healthscienceagency.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will ImageneBio (IMA) present at the 2026 Jefferies Global Healthcare Conference?

ImageneBio will present on June 4, 2026, at 12:50 PM EDT. According to the company, CEO Kristin Yarema, Ph.D., will lead the session as part of the New York Jefferies Global Healthcare Conference agenda.

Who will represent ImageneBio (IMA) at the 2026 Jefferies Global Healthcare Conference in New York?

ImageneBio will be represented by CEO Kristin Yarema, Ph.D. According to the company, she will deliver the formal presentation, while management will also participate in one-on-one meetings with investors during the Jefferies Global Healthcare Conference.

How can investors access ImageneBio’s (IMA) Jefferies Global Healthcare Conference 2026 webcast?

Investors can access the live webcast via the link provided by ImageneBio. According to the company, the webcast will also be archived on the events page of the Imagene investor relations website for 90 days after the presentation.

What is the significance of ImageneBio (IMA) participating in the 2026 Jefferies Global Healthcare Conference?

Participation gives ImageneBio added visibility with institutional investors and healthcare specialists. According to the company, CEO and management will present and hold one-on-one meetings, offering investors insights into Imagene’s strategy, pipeline, and corporate developments in a high-profile conference setting.

Where is the 2026 Jefferies Global Healthcare Conference featuring ImageneBio (IMA) being held?

The Jefferies Global Healthcare Conference with ImageneBio’s presentation will take place in New York. According to the company, CEO Kristin Yarema, Ph.D., presents on June 4, 2026, with webcast access available through the Imagene investor relations website.